The anti-inflammatory peptide Catestatin blocks chemotaxis.
Mϕs
catestatin
chemotaxis
migration
monocytes
neutrophil
pro-angiogenesis
Journal
Journal of leukocyte biology
ISSN: 1938-3673
Titre abrégé: J Leukoc Biol
Pays: England
ID NLM: 8405628
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
pubmed:
24
12
2021
medline:
27
7
2022
entrez:
23
12
2021
Statut:
ppublish
Résumé
Increased levels of the anti-inflammatory peptide Catestatin (CST), a cleavage product of the pro-hormone chromogranin A, correlate with less severe outcomes in hypertension, colitis, and diabetes. However, it is unknown how CST reduces the infiltration of monocytes and macrophages (Mϕs) in inflamed tissues. Here, it is reported that CST blocks leukocyte migration toward inflammatory chemokines. By in vitro and in vivo migration assays, it is shown that although CST itself is chemotactic, it blocks migration of monocytes and neutrophils to inflammatory attracting factor CC-chemokine ligand 2 (CCL2) and C-X-C motif chemokine ligand 2 (CXCL2). Moreover, it directs CX
Identifiants
pubmed: 34939227
doi: 10.1002/JLB.3CRA1220-790RR
pmc: PMC9543570
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Chemokine CCL2
0
Chemokines
0
Chromogranin A
0
Ligands
0
Peptide Fragments
0
Peptides
0
chromogranin A (344-364)
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
273-278Informations de copyright
© 2021 The Authors. Journal of Leukocyte Biology published by Wiley Periodicals LLC on behalf of Society for Leukocyte Biology.
Références
Hypertension. 2021 May 5;77(5):1670-1682
pubmed: 33826401
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Acta Physiol (Oxf). 2021 Jun;232(2):e13655
pubmed: 33783968
Acta Pharmacol Sin. 2012 Mar;33(3):342-50
pubmed: 22367283
J Biol Chem. 1994 Jul 1;269(26):17411-6
pubmed: 7517398
Nat Protoc. 2011 Dec 22;7(1):89-104
pubmed: 22193302
J Clin Med. 2020 Feb 26;9(3):
pubmed: 32110996
Cell Tissue Res. 2019 Apr;376(1):51-70
pubmed: 30467710
Endocr Rev. 2011 Dec;32(6):755-97
pubmed: 21862681
Cell Mol Life Sci. 2005 Feb;62(3):377-85
pubmed: 15723172
Eur J Pharmacol. 2008 Nov 19;598(1-3):104-11
pubmed: 18834877
PLoS One. 2009;4(2):e4501
pubmed: 19225567
Acta Physiol (Oxf). 2008 Feb;192(2):309-24
pubmed: 18005393
J Leukoc Biol. 1994 Nov;56(5):559-64
pubmed: 7964163
J Clin Invest. 2005 Jul;115(7):1942-52
pubmed: 16007257
Pflugers Arch. 2018 Jan;470(1):199-210
pubmed: 29018988
Circulation. 1990 Jan;81(1):185-95
pubmed: 2404624
J Leukoc Biol. 2022 Aug;112(2):273-278
pubmed: 34939227
Circulation. 2008 Jul 15;118(3):247-57
pubmed: 18591442
Immunology. 2011 Apr;132(4):527-39
pubmed: 21214543
J Immunol. 2008 Oct 15;181(8):5711-9
pubmed: 18832730
Immunol Rev. 2019 May;289(1):205-231
pubmed: 30977203
Diabetes. 2018 May;67(5):841-848
pubmed: 29432123
Thromb Haemost. 2018 Jan;118(1):182-194
pubmed: 29304538
J Clin Invest. 1997 Sep 15;100(6):1623-33
pubmed: 9294131
J Interferon Cytokine Res. 2009 Jun;29(6):313-26
pubmed: 19441883
Regul Pept. 2010 Jun 8;162(1-3):33-43
pubmed: 20116404
Front Immunol. 2016 Apr 26;7:160
pubmed: 27199985
Biochem Pharmacol. 2014 Jun 1;89(3):386-98
pubmed: 24637240
Ann N Y Acad Sci. 2019 Nov;1455(1):34-58
pubmed: 31588572
Front Immunol. 2018 Oct 04;9:2199
pubmed: 30337922
Circ Res. 2010 Nov 26;107(11):1326-35
pubmed: 20930149